PortalPublikationenJC polyomavirus replication and associated disease in pediat...

JC polyomavirus replication and associated disease in pediatric renal Transplantation: an international CERTAIN Registry study

Standard

JC polyomavirus replication and associated disease in pediatric renal Transplantation: an international CERTAIN Registry study. / Höcker, Britta; Tabatabai, Julia; Schneble, Lukas; Oh, Jun; Thiel, Florian; Pape, Lars; Rusai, Krisztina; Topaloglu, Rezan; Kranz, Birgitta; Klaus, Günter; Printza, Nikoleta; Yavascan, Onder; Fichtner, Alexander; Krupka, Kai; Bruckner, Thomas; Waldherr, Rüdiger; Pawlita, Michael; Schnitzler, Paul; Hirsch, Hans H; Tönshoff, Burkhard.

in: PEDIATR NEPHROL, Jahrgang 33, Nr. 12, 12.2018, S. 2343-2352.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Höcker, B, Tabatabai, J, Schneble, L, Oh, J, Thiel, F, Pape, L, Rusai, K, Topaloglu, R, Kranz, B, Klaus, G, Printza, N, Yavascan, O, Fichtner, A, Krupka, K, Bruckner, T, Waldherr, R, Pawlita, M, Schnitzler, P, Hirsch, HH & Tönshoff, B 2018, 'JC polyomavirus replication and associated disease in pediatric renal Transplantation: an international CERTAIN Registry study', PEDIATR NEPHROL, Jg. 33, Nr. 12, S. 2343-2352. https://doi.org/10.1007/s00467-018-4029-9

APA

Höcker, B., Tabatabai, J., Schneble, L., Oh, J., Thiel, F., Pape, L., Rusai, K., Topaloglu, R., Kranz, B., Klaus, G., Printza, N., Yavascan, O., Fichtner, A., Krupka, K., Bruckner, T., Waldherr, R., Pawlita, M., Schnitzler, P., Hirsch, H. H., & Tönshoff, B. (2018). JC polyomavirus replication and associated disease in pediatric renal Transplantation: an international CERTAIN Registry study. PEDIATR NEPHROL, 33(12), 2343-2352. https://doi.org/10.1007/s00467-018-4029-9

Vancouver

Höcker B, Tabatabai J, Schneble L, Oh J, Thiel F, Pape L et al. JC polyomavirus replication and associated disease in pediatric renal Transplantation: an international CERTAIN Registry study. PEDIATR NEPHROL. 2018 Dez;33(12):2343-2352. https://doi.org/10.1007/s00467-018-4029-9

Bibtex

@article{7a54bbd36de1428ea2c7e68a7d501186,
title = "JC polyomavirus replication and associated disease in pediatric renal Transplantation: an international CERTAIN Registry study",
abstract = "BACKGROUND: JC polyomavirus (JCPyV)-associated nephropathy (JCPyVAN) is a severe, but rare complication in adult renal transplant (RTx) recipients. Related data in pediatric patients are scarce.METHODS: Based on the CERTAIN Registry, we therefore performed a multi-center, retrospective study on the JCPyV antibody status, prevalence of JCPyV replication, and its associated disease in 139 pediatric RTx recipients (mean age, 8.5 ± 5.3 years). JCPyV DNA in plasma and/or urine was measured by quantitative PCR at a median time of 3.2 (IQR, 0.3-8.1) years post-transplant.RESULTS: 53.2% of patients were JCPyV-seronegative prior to transplantation; younger age was associated with JCPyV seronegativity. 34/139 (24.5%) patients post-transplant showed active JCPyV replication in either urine (22.0%), plasma (13.4%), or both (7.6%). JCPyV viremia occurred significantly (p < 0.001) more often in patients with viruria (34.6%) than in those without (7.6%), but 7/118 (5.9%) had isolated viremia. High-level viruria (> 107 copies/mL) was found in 29.6% of viruric patients. A higher net state of immunosuppression constituted an independent risk factor for JCPyV replication both in urine and plasma (OR 1.2, p < 0.02). Male patients tended to have a higher risk of JCPyV viremia than females (OR 4.3, p = 0.057). There was one male patient (0.7%) with JCPyVAN 7 years post-transplant, which resolved after reduction of immunosuppressive therapy. No patient exhibited progressive multifocal leukoencephalopathy.CONCLUSIONS: This first multi-center study on JCPyV in pediatric renal transplant recipients shows that JCPyV replication is common (24.5%), with strong immunosuppression being a significant risk factor, but associated nephropathy is rare.",
keywords = "Journal Article",
author = "Britta H{\"o}cker and Julia Tabatabai and Lukas Schneble and Jun Oh and Florian Thiel and Lars Pape and Krisztina Rusai and Rezan Topaloglu and Birgitta Kranz and G{\"u}nter Klaus and Nikoleta Printza and Onder Yavascan and Alexander Fichtner and Kai Krupka and Thomas Bruckner and R{\"u}diger Waldherr and Michael Pawlita and Paul Schnitzler and Hirsch, {Hans H} and Burkhard T{\"o}nshoff",
year = "2018",
month = dec,
doi = "10.1007/s00467-018-4029-9",
language = "English",
volume = "33",
pages = "2343--2352",
journal = "PEDIATR NEPHROL",
issn = "0931-041X",
publisher = "Springer",
number = "12",

}

RIS

TY - JOUR

T1 - JC polyomavirus replication and associated disease in pediatric renal Transplantation: an international CERTAIN Registry study

AU - Höcker, Britta

AU - Tabatabai, Julia

AU - Schneble, Lukas

AU - Oh, Jun

AU - Thiel, Florian

AU - Pape, Lars

AU - Rusai, Krisztina

AU - Topaloglu, Rezan

AU - Kranz, Birgitta

AU - Klaus, Günter

AU - Printza, Nikoleta

AU - Yavascan, Onder

AU - Fichtner, Alexander

AU - Krupka, Kai

AU - Bruckner, Thomas

AU - Waldherr, Rüdiger

AU - Pawlita, Michael

AU - Schnitzler, Paul

AU - Hirsch, Hans H

AU - Tönshoff, Burkhard

PY - 2018/12

Y1 - 2018/12

N2 - BACKGROUND: JC polyomavirus (JCPyV)-associated nephropathy (JCPyVAN) is a severe, but rare complication in adult renal transplant (RTx) recipients. Related data in pediatric patients are scarce.METHODS: Based on the CERTAIN Registry, we therefore performed a multi-center, retrospective study on the JCPyV antibody status, prevalence of JCPyV replication, and its associated disease in 139 pediatric RTx recipients (mean age, 8.5 ± 5.3 years). JCPyV DNA in plasma and/or urine was measured by quantitative PCR at a median time of 3.2 (IQR, 0.3-8.1) years post-transplant.RESULTS: 53.2% of patients were JCPyV-seronegative prior to transplantation; younger age was associated with JCPyV seronegativity. 34/139 (24.5%) patients post-transplant showed active JCPyV replication in either urine (22.0%), plasma (13.4%), or both (7.6%). JCPyV viremia occurred significantly (p < 0.001) more often in patients with viruria (34.6%) than in those without (7.6%), but 7/118 (5.9%) had isolated viremia. High-level viruria (> 107 copies/mL) was found in 29.6% of viruric patients. A higher net state of immunosuppression constituted an independent risk factor for JCPyV replication both in urine and plasma (OR 1.2, p < 0.02). Male patients tended to have a higher risk of JCPyV viremia than females (OR 4.3, p = 0.057). There was one male patient (0.7%) with JCPyVAN 7 years post-transplant, which resolved after reduction of immunosuppressive therapy. No patient exhibited progressive multifocal leukoencephalopathy.CONCLUSIONS: This first multi-center study on JCPyV in pediatric renal transplant recipients shows that JCPyV replication is common (24.5%), with strong immunosuppression being a significant risk factor, but associated nephropathy is rare.

AB - BACKGROUND: JC polyomavirus (JCPyV)-associated nephropathy (JCPyVAN) is a severe, but rare complication in adult renal transplant (RTx) recipients. Related data in pediatric patients are scarce.METHODS: Based on the CERTAIN Registry, we therefore performed a multi-center, retrospective study on the JCPyV antibody status, prevalence of JCPyV replication, and its associated disease in 139 pediatric RTx recipients (mean age, 8.5 ± 5.3 years). JCPyV DNA in plasma and/or urine was measured by quantitative PCR at a median time of 3.2 (IQR, 0.3-8.1) years post-transplant.RESULTS: 53.2% of patients were JCPyV-seronegative prior to transplantation; younger age was associated with JCPyV seronegativity. 34/139 (24.5%) patients post-transplant showed active JCPyV replication in either urine (22.0%), plasma (13.4%), or both (7.6%). JCPyV viremia occurred significantly (p < 0.001) more often in patients with viruria (34.6%) than in those without (7.6%), but 7/118 (5.9%) had isolated viremia. High-level viruria (> 107 copies/mL) was found in 29.6% of viruric patients. A higher net state of immunosuppression constituted an independent risk factor for JCPyV replication both in urine and plasma (OR 1.2, p < 0.02). Male patients tended to have a higher risk of JCPyV viremia than females (OR 4.3, p = 0.057). There was one male patient (0.7%) with JCPyVAN 7 years post-transplant, which resolved after reduction of immunosuppressive therapy. No patient exhibited progressive multifocal leukoencephalopathy.CONCLUSIONS: This first multi-center study on JCPyV in pediatric renal transplant recipients shows that JCPyV replication is common (24.5%), with strong immunosuppression being a significant risk factor, but associated nephropathy is rare.

KW - Journal Article

U2 - 10.1007/s00467-018-4029-9

DO - 10.1007/s00467-018-4029-9

M3 - SCORING: Journal article

C2 - 30058047

VL - 33

SP - 2343

EP - 2352

JO - PEDIATR NEPHROL

JF - PEDIATR NEPHROL

SN - 0931-041X

IS - 12

ER -